Towards Healthcare Research & Consulting

U.S. Vaccines Strategic Involvements

Date : 10 June 2026

Latest Updates of Companies in the U.S. Vaccines Market

U.S. Vaccines Market Companies are Pfizer, Moderna, Merck, Sanofi, GlaxoSmithKline

Recent Developments in the U.S. Vaccines Market

  • In June 2026, Moderna, Inc. announced an extended partnership with the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the expansion of a potential vaccine against Bundibugyo ebolavirus (BDBV), a cause of Ebola virus disease for which there are presently no licensed vaccines indicated.
  • In May 2026, SINOVAC received approval from the National Medical Products Administration (NMPA) to launch clinical trials for its Influenza Vaccine, Inactivated.

Market Ecosystem Analysis

Ecosystem Segment Key Participants Role in Market
Technology Providers Moderna, Pfizer, BioNTech, GSK mRNA, adjuvant, recombinant, protein-based vaccine technologies
Product Manufacturers Merck, Pfizer, Sanofi, GSK, CSL Seqirus Commercial vaccine production and supply
Service Providers McKesson, Cencora, Cardinal Health Distribution, cold-chain logistics, vaccine delivery infrastructure
Platform Providers Moderna, Pfizer, BioNTech, Novavax Vaccine development platforms including mRNA and protein technologies
CROs/CDMOs Lonza, Catalent, Fujifilm Diosynth, ICON, Charles River Clinical development and manufacturing support
Software Vendors Veeva Systems, Oracle Health, IQVIA Clinical trial management, pharmacovigilance, vaccine data management
Research Institutions CDC, NIH, Baylor College of Medicine, University of Pennsylvania, Johns Hopkins University Vaccine research, surveillance, clinical development
End-User Industries Hospitals, Retail Pharmacies, Public Health Agencies, Military Healthcare, Academic Medical Centers Vaccine administration and procurement

Value Chain Analysis

R&D

  • Vaccine research and development involves antigen discovery, platform innovation, preclinical testing, formulation optimization, and manufacturing process design. Advanced technologies, genomic insights, and immunological studies improve efficacy, safety, scalability, and protection.
  • Pfizer, Moderna, GSK, Sanofi, Merck & Co., CSL Seqirus, Bharat Biotech

Clinical Trials and Regulatory Approvals

  • Clinical trials evaluate vaccine safety, immunogenicity, efficacy, and dosing across diverse populations through phased studies. Regulatory authorities review comprehensive data, manufacturing standards, and quality controls before granting authorization.
  • Pfizer, Moderna, AstraZeneca, GSK, Sanofi, Novavax, Johnson & Johnson

Patient Support and Services

  • Patient support and services include vaccination awareness programs, appointment scheduling, distribution networks, adverse event monitoring, follow-up reminders, and educational resources. These initiatives enhance accessibility, adherence, confidence, and outcomes.
  • Pfizer, GSK, Sanofi, Merck & Co., CSL Seqirus, Bavarian Nordic, Serum Institute of India
Tier 1
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to Keyword
Merck & Co. Rahway, New Jersey USA Leading vaccine franchise with Gardasil and pediatric portfolio; among the largest vaccine revenue generators globally Gardasil 9, M-M-R II, Varivax, Vaxneuvance, RotaTeq
Pfizer New York, New York USA Major U.S. vaccine supplier with broad respiratory and pediatric vaccine portfolio Prevnar 20, Abrysvo, Trumenba, Comirnaty
GSK Brentford, England United Kingdom Global leader in adult immunization and adjuvant technology Shingrix, Arexvy, Bexsero, Boostrix
Sanofi Paris France Strong U.S. influenza and pediatric vaccine presence through Sanofi Pasteur Fluzone, MenQuadfi, Pentacel, Vaxelis
Moderna Cambridge, Massachusetts USA Major mRNA vaccine innovator with growing respiratory vaccine franchise Spikevax, mRESVIA, mRNA pipeline vaccines
Tier 2
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to Keyword
CSL Melbourne, Victoria Australia Major influenza vaccine supplier in the U.S. market Fluad, Flucelvax, Afluria
Novavax Gaithersburg, Maryland USA Commercial protein-based vaccine developer with Sanofi partnership Nuvaxovid platform, combination vaccine programs
AstraZeneca Cambridge, England United Kingdom Active in respiratory vaccines and pandemic preparedness RSV and respiratory vaccine pipeline
Dynavax Technologies Emeryville, California USA Commercial vaccine developer with differentiated adjuvant technology Heplisav-B, CpG 1018 adjuvant
Bavarian Nordic Hellerup Denmark Established specialty vaccine supplier to U.S. government agencies Jynneos, Rabies Vaccine, Smallpox Vaccines
Tier 3
Company Name Headquarters Country Why Relevant to This Market Key Products/Services Related to Keyword
BioNTech Mainz Germany Expanding U.S. vaccine presence through mRNA programs and partnerships mRNA vaccine platform
Inovio Pharmaceuticals Plymouth Meeting, Pennsylvania USA DNA vaccine specialist with infectious disease pipeline DNA vaccine platform
Vaxcyte San Carlos, California USA Fast-growing pneumococcal vaccine developer VAX-24, VAX-31
Altimmune Gaithersburg, Maryland USA Vaccine platform developer with infectious disease expertise Intranasal vaccine technologies
Emergent BioSolutions Gaithersburg, Maryland USA Important biodefense and government vaccine supplier Anthrax and biodefense vaccines

U.S. Vaccines Market Trends for 2026

The U.S. Vaccines market size touched US$ 38.24 billion in 2025, with expectations of climbing to US$ 39.88 billion in 2026 and hitting US$ 58.26 billion by 2035, driven by a CAGR of 4.3% over the forecast period.

U.S. Vaccines Market Size is USD 39.88 Billion in 2026.